Our analysis established that assuming a willingness-to-pay threshold of $163,371/life year (quality-adjusted life year) for the German model and $188,559/life year (quality-adjusted life year) for the US model, cabozantinib is not cost-effective compared with best supportive care. Sensitivity analyses showed that cabozantinib was not cost-effective in almost all our scenarios.
No takes yet. Share an insight, caveat, or question.
Sieg et al. (2020) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: